Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.11
ALR's Cash to Debt is ranked lower than
53% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.05 vs. ALR: 0.11 )
ALR' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.11

Equity to Asset 0.30
ALR's Equity to Asset is ranked higher than
53% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. ALR: 0.30 )
ALR' s 10-Year Equity to Asset Range
Min: -0.49   Max: 0.77
Current: 0.3

-0.49
0.77
Interest Coverage 0.50
ALR's Interest Coverage is ranked lower than
59% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.50 vs. ALR: 0.50 )
ALR' s 10-Year Interest Coverage Range
Min: 0.05   Max: 2.56
Current: 0.5

0.05
2.56
F-Score: 5
Z-Score: 0.41
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 4.45
ALR's Operating margin (%) is ranked higher than
73% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.76 vs. ALR: 4.45 )
ALR' s 10-Year Operating margin (%) Range
Min: -47.12   Max: 11.39
Current: 4.45

-47.12
11.39
Net-margin (%) -2.35
ALR's Net-margin (%) is ranked higher than
66% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. ALR: -2.35 )
ALR' s 10-Year Net-margin (%) Range
Min: -149.74   Max: 6.25
Current: -2.35

-149.74
6.25
ROE (%) -3.43
ALR's ROE (%) is ranked higher than
64% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.60 vs. ALR: -3.43 )
ALR' s 10-Year ROE (%) Range
Min: -205.76   Max: 8.77
Current: -3.43

-205.76
8.77
ROA (%) -1.01
ALR's ROA (%) is ranked higher than
66% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. ALR: -1.01 )
ALR' s 10-Year ROA (%) Range
Min: -69.59   Max: 4.99
Current: -1.01

-69.59
4.99
ROC (Joel Greenblatt) (%) 12.99
ALR's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. ALR: 12.99 )
ALR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -227.79   Max: 86.34
Current: 12.99

-227.79
86.34
Revenue Growth (%) 13.30
ALR's Revenue Growth (%) is ranked higher than
89% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. ALR: 13.30 )
ALR' s 10-Year Revenue Growth (%) Range
Min: -22.2   Max: 71.9
Current: 13.3

-22.2
71.9
EPS Growth (%) -55.10
ALR's EPS Growth (%) is ranked higher than
50% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. ALR: -55.10 )
ALR' s 10-Year EPS Growth (%) Range
Min: -55.1   Max: 75.3
Current: -55.1

-55.1
75.3
» ALR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ALR Guru Trades in Q3 2013

Paul Tudor Jones 21,100 sh (+142.53%)
Steven Cohen 26,489 sh (+75.42%)
Jim Simons 761,824 sh (+2.79%)
Diamond Hill Capital 801,161 sh (+2.06%)
Mario Gabelli 10,000 sh (unchged)
Pioneer Investments 74,600 sh (unchged)
Jeremy Grantham Sold Out
Chuck Royce 561,700 sh (-8.55%)
Manning & Napier Advisors, Inc 5,140,664 sh (-25.2%)
Private Capital 927,844 sh (-41.64%)
» More
Q4 2013

ALR Guru Trades in Q4 2013

Diamond Hill Capital 869,632 sh (+8.55%)
Mario Gabelli 10,600 sh (+6%)
Jim Simons 792,324 sh (+4%)
Private Capital 928,024 sh (+0.02%)
Pioneer Investments Sold Out
Chuck Royce 554,200 sh (-1.34%)
Manning & Napier Advisors, Inc 4,824,612 sh (-6.15%)
Steven Cohen 22,748 sh (-14.12%)
Paul Tudor Jones 8,700 sh (-58.77%)
» More
Q1 2014

ALR Guru Trades in Q1 2014

Pioneer Investments 272,081 sh (New)
Steven Cohen 242,783 sh (+967.27%)
Mario Gabelli 79,145 sh (+646.65%)
Diamond Hill Capital 986,820 sh (+13.48%)
Chuck Royce 615,700 sh (+11.1%)
Private Capital 935,449 sh (+0.8%)
Paul Tudor Jones Sold Out
Manning & Napier Advisors, Inc 4,809,827 sh (-0.31%)
Jim Simons 294,324 sh (-62.85%)
» More
Q2 2014

ALR Guru Trades in Q2 2014

Joel Greenblatt 11,057 sh (New)
John Keeley 1,335,700 sh (New)
Paul Tudor Jones 5,800 sh (New)
Mario Gabelli 242,845 sh (+206.84%)
Pioneer Investments 469,046 sh (+72.39%)
Chuck Royce 686,700 sh (+11.53%)
Diamond Hill Capital 1,066,212 sh (+8.05%)
Private Capital 920,989 sh (-1.55%)
Manning & Napier Advisors, Inc 4,431,073 sh (-7.87%)
Jim Simons 74,924 sh (-74.54%)
» More
» Details

Insider Trades

Latest Guru Trades with ALR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Keeley 2014-06-30 New Buy0.9%$32.86 - $37.68 $ 35.01-2%1335700
Mario Gabelli 2014-06-30 Add 206.84%0.03%$32.86 - $37.68 $ 35.01-2%242845
Joel Greenblatt 2014-06-30 New Buy0.01%$32.86 - $37.68 $ 35.01-2%11057
Mario Gabelli 2014-03-31 Add 646.65%0.01%$33.99 - $39.34 $ 35.01-4%79145
Seth Klarman 2012-06-30 Sold Out 0.12%$17.98 - $25.97 $ 35.0168%0
Mario Gabelli 2012-06-30 Reduce -25.93%$17.98 - $25.97 $ 35.0168%10000
Seth Klarman 2012-03-31 Reduce -93.12%1.3%$22.21 - $26.64 $ 35.0153%137700
Seth Klarman 2011-12-31 Reduce -35.48%0.72%$18.51 - $26.43 $ 35.0152%2000000
David Dreman 2011-12-31 Sold Out 0.53%$18.51 - $26.43 $ 35.0152%0
Mario Gabelli 2011-12-31 Reduce -27.03%$18.51 - $26.43 $ 35.0152%13500
George Soros 2011-06-30 Sold Out $33.98 - $41 $ 35.01-8%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB15.423.90

Ratios

vs
industry
vs
history
P/B 1.98
ALR's P/B is ranked higher than
85% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.38 vs. ALR: 1.98 )
ALR' s 10-Year P/B Range
Min: 0.42   Max: 2.75
Current: 1.98

0.42
2.75
P/S 0.97
ALR's P/S is ranked higher than
90% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.42 vs. ALR: 0.97 )
ALR' s 10-Year P/S Range
Min: 0.52   Max: 4.12
Current: 0.97

0.52
4.12
PFCF 16.91
ALR's PFCF is ranked higher than
88% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALR: 16.91 )
ALR' s 10-Year PFCF Range
Min: 8.97   Max: 2693
Current: 16.91

8.97
2693
EV-to-EBIT 89.64
ALR's EV-to-EBIT is ranked higher than
72% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALR: 89.64 )
ALR' s 10-Year EV-to-EBIT Range
Min: 25.7   Max: 2833.4
Current: 89.64

25.7
2833.4
Current Ratio 2.25
ALR's Current Ratio is ranked higher than
65% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. ALR: 2.25 )
ALR' s 10-Year Current Ratio Range
Min: 0.7   Max: 3.42
Current: 2.25

0.7
3.42
Quick Ratio 1.70
ALR's Quick Ratio is ranked higher than
58% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. ALR: 1.70 )
ALR' s 10-Year Quick Ratio Range
Min: 0.46   Max: 2.89
Current: 1.7

0.46
2.89

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.87
ALR's Price/DCF (Projected) is ranked higher than
97% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALR: 0.87 )
ALR' s 10-Year Price/DCF (Projected) Range
Min: 0.43   Max: 7.04
Current: 0.87

0.43
7.04
Price/Median PS Value 0.72
ALR's Price/Median PS Value is ranked higher than
91% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. ALR: 0.72 )
ALR' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 7.24
Current: 0.72

0.39
7.24
Earnings Yield (Greenblatt) 1.10
ALR's Earnings Yield (Greenblatt) is ranked lower than
62% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. ALR: 1.10 )
ALR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 3.9
Current: 1.1

0.3
3.9
Forward Rate of Return (Yacktman) 4.21
ALR's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. ALR: 4.21 )
ALR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.2   Max: 9.4
Current: 4.21

-0.2
9.4

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:IM5.Germany
Alere Inc formerly known as Inverness Medical Innovations, Inc. is a Delaware corporation, which was formed to acquire the women's health, nutritional supplements and professional diagnostics businesses of its predecessor, Inverness Medical Technology, Inc., through a split-off and merger transaction, which occurred in November 2001. The Company enables individuals to take charge of improving their health and quality of life at home by developing new capabilities in near-patient diagnosis, monitoring and health management. The Company's global products and services, as well as its new product development efforts, focuses on cardiology, infectious disease, toxicology, diabetes, oncology and women's health. The Company's main reportable operating segments are professional diagnostics, health management and consumer diagnostics. Professional diagnostics are generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals and doctors' offices and, increasingly, testing and monitoring done at home at the direction of the medical professional, or through patient self-testing. Professional diagnostic products provide for qualitative or quantitative analysis of a patient's body fluids or tissue for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. The Company's health management business strives to empower participants of its programs and physicians so they could work together towards better health. It also provides services supporting home INR testing. Its health management business is principally conducted in the United States. The Company's other current consumer diagnostic products consist of its market-leading First Check brand of over-the-counter drugs of abuse tests for at-home testing for up to seven illicit drugs and five prescription drugs, as well as First Check brand over-the-counter tests for alcohol abuse, cholesterol monitoring and colon cancer screening. The Company's manufacturing facilities are located in San Diego, California; Scarborough, Maine; Dundee, Scotland; Oslo, Norway; Hangzhou and Shanghai, China; Matsudo, Japan; and Yongin, South Korea. It also manufactures products at a number of other facilities in the United States, Australia, Germany, India, Israel, South Africa, Spain and the United Kingdom. Its competitors in the United States and abroad are numerous and include, among others, diagnostic testing and medical products companies, universities and other research institutions, health management service providers, healthcare providers and health insurers. The main competitors for its professional rapid diagnostic products are Becton Dickinson, Quidel and Meridian Bioscience.
» More Articles for ALR

Headlines

Articles On GuruFocus.com
Carl Icahn Bets on Hologic; Should You? Aug 19 2014 
Corsair Capital's Investment Thesis on Alere Inc. Jan 23 2014 
Private Capital Management Sells Update Nov 27 2013 
Performance - 11/15/2013 Nov 17 2013 
Microcap Man Chuck Royce Reveals Top New Stock Buys Feb 07 2013 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Are Regional Banks Free from European Exposure? Jan 27 2012 
Alere Inc.: Foreign Currency Translations and the Euro Dec 21 2011 
Alere, Inc ,Foreign Currency Translations and the Euro. Dec 21 2011 
Diamond Hill Capital's Top 5 Third Quarter New Buys Oct 21 2011 

More From Other Websites
Alro in H1 2014: higher sales of processed aluminium, despite low international market Aug 20 2014
Altera Releases Quartus II Software Arria 10 Edition v14.0 Aug 18 2014
ALERE INC. Financials Aug 13 2014
Alere to Attend Canaccord Genuity Conference Aug 08 2014
Alere to Attend Canaccord Genuity Conference Aug 08 2014
ALERE INC. Files SEC form 10-Q, Quarterly Report Aug 06 2014
Alere (ALR) Is Today's Dead Cat Bounce Stock Aug 05 2014
Alere Q2 Earnings and Revenues Miss, Deteriorate Y/Y Aug 05 2014
Will This Price Target Decrease Hurt Alere (ALR) Stock Today? Aug 05 2014
Why Alere (ALR) Stock Is Down Today Aug 04 2014
Altera Enables Customer Design Starts for 14 nm Stratix 10 FPGAs and SoCs Aug 04 2014
ALERE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 04 2014
Alere Inc. Announces Second Quarter 2014 Results Aug 04 2014
Q2 2014 Alere Inc Earnings Release - Before Market Open Aug 04 2014
Alere Inc Stock Upgraded (ALR) Jul 25 2014
Alere Inc. Schedules Conference Call for 8:30 a.m. ET August 4, 2014 to Discuss Second Quarter 2014... Jul 25 2014
Alere Earns Ethical and Quality Certification for Educational Anticoagulation Website Jul 21 2014
Alere's Diagnostic Test Shows Accurate HIV Detection in Infants Jul 15 2014
New Alere™ q Point-of-Care Early Infant Diagnosis Test Prototype Accurately Detects HIV in Infants... Jul 14 2014
New Alere™ q Point-of-Care Early Infant Diagnosis Test Prototype Accurately Detects HIV in Infants... Jul 14 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide